trending Market Intelligence /marketintelligence/en/news-insights/trending/7yqJREUTENxnS2jBvPLkQQ2 content esgSubNav
In This List

Verrica to seek approval for skin treatment after positive results in 2 trials

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Verrica to seek approval for skin treatment after positive results in 2 trials

Verrica Pharmaceuticals Inc. said it will seek U.S. approval for its skin treatment VP-102 during the second half of the year after it cleared two late-stage studies.

The Camp-1 and Camp-2 clinical trials evaluated the efficacy and safety of VP-102 against placebo in 528 patients with molluscum contagiosum — a common skin disease that occurs mainly in children. The U.S. Food and Drug Administration has yet to approve a treatment for the disease, which is caused by a poxvirus and affects about 6 million people in the U.S. each year.

VP-102 achieved complete clearance of all treatable lesions in 46% and 54% patients after 84 days of treatment in the Camp-1 and Camp-2 phase 3 studies, respectively. This compares to the 18% and 13% of patients in the placebo groups.

The West Chester, Pa.-based drugmaker said the medicine did not cause any major side effects.